SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently trending as it pushes to new all-time highs, signaling a potential breakout phase that has the community divided between bullish momentum chasers and those skeptical of its massive market valuation. Investors are actively debating whether this movement marks the start of a sustained expansion or a temporary peak ahead of upcoming earnings, with many monitoring the stock as a bellwether for the broader semiconductor sector.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a massive sell-off after Marvell cancelled all purchase orders citing an NDA breach, fueling intense community debate over management's professional conduct and the future viability of their technology. Investors are actively questioning the company's credibility and long-term path forward, with discussions centered on potential legal fallout, executive accountability, and whether this represents a total loss of trust or a speculative buying opportunity.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing significant retail interest driven by its status as a high-volatility, low-float stock capable of rapid price movements. Community sentiment remains highly polarized, with active discussions focused on the potential for short squeezes, recent corporate governance updates, and skepticism surrounding the stock's long-term sustainability.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors digest the strategic consolidation of its Tanbreez rare earth asset and the potential impact of a significant share-canceling acquisition of European Lithium. The community is actively debating the stock's role in securing Western defense supply chains and closely monitoring institutional activity and borrowing costs as indicators of a potential short squeeze.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a major focus for traders as the market digests recent Phase 3 trial results for its gene-editing candidate, with community sentiment split between those viewing the data as a revolutionary clinical breakthrough and those concerned about commercialization risks. While some investors are betting on a potential short squeeze given the stock's high short interest, others are actively debating the impact of the company's ATM offering and clinical trial safety profiles.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending as investors digest a solid quarterly earnings beat, with strong sales growth driven by aggressive value strategies and loyalty program engagement. The stock has seen heightened activity and volatility as traders weigh the chain's ability to maintain resilient performance amid persistent inflation and shifting consumer dining habits.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing a surge driven by significant institutional accumulation, aggressive insider buying, and positive clinical momentum surrounding its paridiprubart trial results. Community members are actively speculating about potential buyout scenarios and near-term regulatory catalysts, while debating the impact of the stock's low effective float on its recent volatile price action.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened investor attention as community members debate its potential for a turnaround, driven by optimism regarding upcoming earnings, a massive stock buyback program, and rumors of a strategic smartphone processor partnership with OpenAI. While many bulls view the stock as undervalued and primed for a rotation, others remain skeptical, pointing to persistent overhead supply and disappointment over its recent price action following the announcement of AI-related collaborations.

PolySwarm

PolySwarm (NCT) is trending as the community speculates on an imminent breakout, fueled by its low float and perceived undervaluation in the cybersecurity sector. Investors are actively debating potential price action and accumulation strategies while closely monitoring whale activity and high-volume triggers.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently attracting investor attention following a positive Phase 3 clinical trial readout for its denifanstat treatment in acne patients, which bolsters its pipeline and clinical derisking narrative. The community is actively discussing the stock's long-term potential in the MASH and acne markets, while closely monitoring institutional accumulation and potential interest from larger pharmaceutical players for a future partnership or acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights PR Newswire TEL AVIV...

Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200 Day Moving Average   - Here's What Happened

Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200 Day Moving Average - What's Next...

Dow Falls Over 200 Points; Tesla Shares Slip After Q1 Results

Dow Jones drops 0.44%, NASDAQ falls 0.31%, S&P 500 down 0.22%. Tesla shares drop 1% after reporting earnings. Auddia Inc. and Cumberland Pharmaceuticals Inc. see significant gains.read more...

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business...

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity...

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR...

Cumberland Pharmaceuticals Launches New Sancuso Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Cumberland Pharmaceuticals Launches New Sancuso Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting Cumberland Pharmaceuticals Launches New Sancuso Website Featuring...

Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales

CPIX's Q4 revenues jump 31%, while loss narrows year over year as sales of Vibativ, Sancuso and new product Talicia boosted its performance.

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036)  DelveInsight

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight H. pylori Infections Market in the 6MM to Observe...

Cumberland Pharmaceuticals Q4 Earnings Call Highlights

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported fourth-quarter and full-year 2025 results and provided a business update during its earnings call, highlighting revenue growth across its portfolio...

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Current Price	$4.24
Prev Close	$4.06
Open	$4.10
Dividend Yield	0.00%
50-Day Moving Average	$3.44
Beta	0.65
Avg. Volume	98,681.63
PE Ratio	-21.22

52-Week High	$6.27
52-Week Low	$1.85
Market Capitalization	$60.72M
EPS (Annual)	-$0.1909
Price to Book	2.44
Revenue Per Employee	$478,725.07

CPIX
Cumberland Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CPIX News

CPIXCumberland Pharmaceuticals Inc.